Examining the role of epigenetic age in myeloproliferative neoplasms
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
This study is trying to see if the biological age of DNA can help predict how well people with myeloproliferative neoplasms will do and if they might face complications like blood clots.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT06022328 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between epigenetic age and clinical outcomes in patients with myeloproliferative neoplasms (MPN), including essential thrombocythemia, polycythemia vera, and primary myelofibrosis. By analyzing DNA methylation patterns at diagnosis, the study aims to determine how epigenetic age correlates with thrombotic events and the progression of these hematological malignancies. The research utilizes established epigenetic clocks to assess aging and its potential impact on patient prognosis. The findings could enhance understanding of MPN complications and improve risk stratification for affected individuals.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with polycythemia vera, essential thrombocythemia, or primary myelofibrosis who have not undergone treatments affecting DNA methylation.
Not a fit: Patients with other hematological malignancies or those receiving treatments that impact DNA methylation are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and tailored treatment strategies for patients with myeloproliferative neoplasms.
How similar studies have performed: While the approach of using epigenetic age in cancer prognosis is emerging, this specific application in myeloproliferative neoplasms is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For the 110 patients with MPN: * Patients with PV, ET or PMF * DNA extracted from purified granulocytes at time of diagnosis * No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) For the 10 subjects without MPN: * Absence of hematological malignancy * Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia * Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) Exclusion Criteria: For the 110 patients with MPN: * Patients without PV, ET or PMF * Patients without purified granulocytes DNA available at time of diagnosis * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling * Patients with less than 2 years' follow-up For the 10 subjects in NMP : * Patients with hematological malignancy and/or solid cancer * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
Where this trial is running
Bordeaux
- CHU de Bordeaux, service Hématologie Biologique — Bordeaux, France (Recruiting)
Study contacts
- Study coordinator: Olivier MANSIER
- Email: olivier.mansier@chu-bordeaux.fr
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.